Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Perioperative RT with systemic therapy improves survival in SCLC patients

12 Nov 2025

The combination of preoperative systemic therapy (PRST) with preoperative radiotherapy (PRRT) leads to significant improvements in overall survival (OS) among squamous cell lung cancer (SCLC) patients with pathologic N2, reports a study.

Perioperative RT with systemic therapy improves survival in SCLC patients

12 Nov 2025

Nonintubated surgery for lung biopsy delivers better outcomes in ILD patients

12 Nov 2025 bởi

A recent study has shown the benefits of nonintubated video-assisted thoracic surgery (NIVATS), which offers better preservation of respiratory function, a good diagnostic yield, and improved overall outcomes after surgical lung biopsy in patients with interstitial lung disease (ILD) compared with intubated VATS (IVATS).

Nonintubated surgery for lung biopsy delivers better outcomes in ILD patients

12 Nov 2025

Rapid and reliable detection of SARS-CoV-2 and influenza in real-world settings

12 Nov 2025

As seasonal influenza returns amid ongoing SARS-CoV-2 circulation, rapid differentiation between these infections has become crucial for enabling early and effective patient care. Researchers conducted the largest prospective, multicentre evaluation to date of the Panbio COVID-19/Flu A&B Panel (Abbott)—a single-strip antigen test designed to detect SARS-CoV-2, influenza A, and influenza B from mid-turbinate nasal swabs (NMT) in symptomatic individuals. [J Clin Microbiol 2024;62:e0020724]

Rapid and reliable detection of SARS-CoV-2 and influenza in real-world settings

12 Nov 2025

Nonpharmacological intervention for ILO ready for evaluation

11 Nov 2025

Researchers have recently developed a nonpharmacological intervention, dubbed the upper airway control therapy (U-ACT), for inducible laryngeal obstruction (ILO).

Nonpharmacological intervention for ILO ready for evaluation

11 Nov 2025

Post-exertional malaise prevalent in adults with long COVID

10 Nov 2025 bởi

A systematic review and meta-analysis reports a high prevalence of post-exertional malaise (PEM) in individuals with post-COVID-19 condition (PCC).

Post-exertional malaise prevalent in adults with long COVID

10 Nov 2025

Long-term LVEF decline occurs following COVID-19

08 Nov 2025 bởi

Individuals with SARS‐CoV‐2 infection, especially those who are hospitalized, face long‐term declines in left ventricular ejection fraction (LVEF), according to a retrospective study.

Long-term LVEF decline occurs following COVID-19

08 Nov 2025

Patients with serious mental illness at high risk of postacute sequelae of SARS-CoV-2

06 Nov 2025

Among patients who sustained COVID-19 infection, the risk of postacute sequelae of SARS-CoV-2 (PASC) is high in the presence of a serious mental illness, according to a study.

Patients with serious mental illness at high risk of postacute sequelae of SARS-CoV-2

06 Nov 2025

Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC

05 Nov 2025 bởi

An updated analysis of MARIPOSA reveals significant reductions in the incidence of MET and EGFR resistance alterations with first-line amivantamab plus lazertinib compared with osimertinib, with no upregulation in other resistance pathways, in patients with nonsmall cell lung cancer (NSCLC).

Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC

05 Nov 2025

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

05 Nov 2025 bởi

Treatment with tislelizumab results in longer overall survival (OS), prolonged progression-free survival (PFS), higher objective response rates (ORRs), more durable responses, and fewer grade ≥3 treatment-emergent (TEAEs) and treatment-related adverse events (TRAEs) compared with docetaxel, according to the RATIONALE-303 study.

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

05 Nov 2025

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

04 Nov 2025 bởi

Neoadjuvant treatment with tiragolumab plus atezolizumab, with or without chemotherapy, is feasible in advanced resectable non-small cell lung cancer (NSCLC), having an acceptable safety profile and yielding major pathologic response (MPR) rates comparable to that observed with other perioperative immunotherapy plus chemotherapy regimens, according to the phase II SKYSCRAPER-05 trial.

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

04 Nov 2025

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Perioperative RT with systemic therapy improves survival in SCLC patients

Perioperative RT with systemic therapy improves survival in SCLC patients

Nonintubated surgery for lung biopsy delivers better outcomes in ILD patients

Nonintubated surgery for lung biopsy delivers better outcomes in ILD patients

Rapid and reliable detection of SARS-CoV-2 and influenza in real-world settings

Rapid and reliable detection of SARS-CoV-2 and influenza in real-world settings

Nonpharmacological intervention for ILO ready for evaluation

Nonpharmacological intervention for ILO ready for evaluation

Post-exertional malaise prevalent in adults with long COVID

Post-exertional malaise prevalent in adults with long COVID

Long-term LVEF decline occurs following COVID-19

Long-term LVEF decline occurs following COVID-19

Patients with serious mental illness at high risk of postacute sequelae of SARS-CoV-2

Patients with serious mental illness at high risk of postacute sequelae of SARS-CoV-2

Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC

Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC